Zealand Pharma Company Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism.
The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.
The company was incorporated in 1997 and is based in Søborg, Denmark.
![Zealand Pharma logo](https://img.stockanalysis.com/logos1/CO/ZEAL.png)
Country | Denmark |
Founded | 1997 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 253 |
CEO | Adam Steensberg |
Contact Details
Address: Sydmarken 11 Søborg, 2860 Denmark | |
Phone | 45 88 77 36 00 |
Website | zealandpharma.com |
Stock Details
Ticker Symbol | ZEAL |
Exchange | Nasdaq Copenhagen |
Fiscal Year | January - December |
Reporting Currency | DKK |
ISIN Number | DK0060257814 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Adam Sinding Steensberg M.D. | President and Chief Executive Officer |
Henriette Wennicke | Executive Vice President and Chief Financial Officer |
Ivan Mourits Moller | Executive Vice President and Chief Operating Officer |
Dr. David M. Kendall M.D. | Chief Medical Officer and Head of Research & Development |
Mads Kronborg | Head of Investor Relations and Communication |
Ravinder Singh Chahil | Executive Vice President and General Counsel |
Christina Sonnenborg Bredal | Executive Vice President and Chief People Officer |
Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology |
Dr. Danilo Verge | Head of Global Medical Affairs |
Lykke Romer | Vice President and Head of Finance and Accounting |